Trinity Biotech names diabetes care veteran as biosensor marketing director

DUBLIN, Aug. 20, 2024 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB), a commercial biotechnology company focused on human diagnostics and diabetes management solutions, including portable biosensors, today announces the appointment of David Ouston as Chief Marketing Officer, Biosensors. Mr. Ouston brings extensive commercial experience driving growth in glucose monitoring devices at large, established companies in global markets.

John Gillard, President and CEO of Trinity Biotech, said: “We continue to focus on our innovative, needle-free, reusable continuous glucose monitoring (CGM) technology as a key long-term growth driver for Trinity Biotech and are pleased to welcome David as a strategic addition to our growing team to help us execute on this mission. His extensive experience in global leadership in the promotion and market access strategy of diabetes devices and digital solutions will be a strong asset to Trinity Biotech as we prepare to launch our proprietary CGM in the rapidly growing diabetes and wellness markets.”

Commenting on his appointment, Mr. Ouston said, “I am excited to join Trinity Biotech to help realize the vision of accessible and innovative CGM for global markets. The Trinity device offers a promising and exciting innovation in wearable biosensor technology and wellness analytics that has the potential to benefit more people around the world to improve public health. I am excited to work with this impressive team to deliver a truly groundbreaking and valuable solution to global markets.”

Mr Ouston’s career spans 16 years in the glucose monitoring and diabetes health sectors, including global and regional EMEA marketing roles at Johnson & Johnson and LifeScan, where he led innovation for the OneTouch glucose monitoring portfolio. Prior to that, he held marketing roles at private healthcare provider Bupa, where he supported the promotion of their global healthcare brand. Mr Ouston holds a Bachelor of Business Administration from Brunel University, UK

Forecast statements

This press release contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including, but not limited to, statements regarding Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and operating results. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” “anticipates” or words of similar meaning and do not reflect historical facts. Certain forward-looking statements in this release may be subject to risks and uncertainties, including, but not limited to, our ability to capitalize on the purchase of Waveform’s assets, our continued listing on the Nasdaq Stock Exchange, our ability to operate profitably in the future, the impact of the spread of COVID-19 and its variants, potential inventory overages and inventory imbalances at the company’s distributors, system losses or failures with respect to Trinity Biotech’s facilities or manufacturing operations, the impact of currency fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, market acceptance of Trinity Biotech’s products and services, the continued development of its products, required governmental approvals, risks related to the production and distribution of its products on a commercial scale without defects, risks related to the introduction of new instruments manufactured by third parties, risks related to competition in the human diagnostics market, risks related to the protection of Trinity Biotech’s intellectual property or intellectual property infringement claims by third parties, risks related to the state of the United States economy and other risks more fully described in the “Risk Factors” section. in Trinity Biotech’s Annual Report on Form 20-F for the fiscal year ended December 31, 2023 and in Trinity Biotech’s other periodic reports filed from time to time with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. Trinity Biotech does not undertake, and expressly disclaims, any obligation to update any forward-looking statements.

About Trinity Biotech

Trinity Biotech is a commercial biotechnology company focused on human diagnostics and diabetes management solutions, including portable biosensors. The company develops, acquires, manufactures and markets diagnostic systems, including reagents and measurement devices, for the point-of-care and clinical laboratory segments of the diagnostic market and recently entered the portable biosensor industry with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, beginning with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify hemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells directly in the United States and through a network of international distributors and strategic partners in more than 75 countries worldwide. For more information, visit the company’s website: www.trinitybiotech.com.